Pluristem Therapeutics - Termination of coverage
Edison Investment Research is terminating coverage on Pluristem Therapeutics (PSTI). Please note you should no longer rely on any previous research...
48 Views
Pluristem Therapeutics - FY18 results and top-line claudication data
Pluristem ended FY18 with an operating loss of $33.7m mostly attributed to R&D expenditure ($22.6m) and as of 30 June 2018 had $30.6m in net...
53 Views
Pluristem Therapeutics - FDA gives two programs the green light with IND
In April 2018, Pluristem announced that the FDA had given two pipeline programs IND clearance: PLX-PAD for femoral neck fracture (FNF) healing and...
74 Views
Pluristem Therapeutics - New avenues of study
Pluristem continues to advance its PLX technology platform. In a recent paper it investigated the application of these cells for their ability to...
86 Views
Pluristem Therapeutics - Progress continues
Pluristem Therapeutics has had a productive FY18 to date. The company is advancing PLX-PAD in its Phase III study of critical limb ischemia (CLI)...
41 Views
No more insights